These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2660 related items for PubMed ID: 19490988

  • 1. Valproic acid in pregnancy: how much are we endangering the embryo and fetus?
    Ornoy A.
    Reprod Toxicol; 2009 Jul; 28(1):1-10. PubMed ID: 19490988
    [Abstract] [Full Text] [Related]

  • 2. Neuroteratogens in man: an overview with special emphasis on the teratogenicity of antiepileptic drugs in pregnancy.
    Ornoy A.
    Reprod Toxicol; 2006 Aug; 22(2):214-26. PubMed ID: 16621443
    [Abstract] [Full Text] [Related]

  • 3. Exencephaly and axial skeletal malformations induced by maternal administration of sodium valproate in the MF1 mouse.
    Padmanabhan R, Hameed MS.
    J Craniofac Genet Dev Biol; 1994 Aug; 14(3):192-205. PubMed ID: 7852547
    [Abstract] [Full Text] [Related]

  • 4. Folic acid and pantothenic acid protection against valproic acid-induced neural tube defects in CD-1 mice.
    Dawson JE, Raymond AM, Winn LM.
    Toxicol Appl Pharmacol; 2006 Mar 01; 211(2):124-32. PubMed ID: 16112698
    [Abstract] [Full Text] [Related]

  • 5. Myo-inositol enhances teratogenicity of valproic acid in the mouse.
    Massa V, Wlodarczyk B, Giavini E, Finnell RH.
    Birth Defects Res A Clin Mol Teratol; 2006 Mar 01; 76(3):200-4. PubMed ID: 16511884
    [Abstract] [Full Text] [Related]

  • 6. Hydroxamic acid and fluorinated derivatives of valproic acid: anticonvulsant activity, neurotoxicity and teratogenicity.
    Gravemann U, Volland J, Nau H.
    Neurotoxicol Teratol; 2008 Mar 01; 30(5):390-4. PubMed ID: 18455366
    [Abstract] [Full Text] [Related]

  • 7. Benzodiazepine amplification of valproate teratogenic effects in children of mothers with absence epilepsy.
    Laegreid L, Kyllerman M, Hedner T, Hagberg B, Viggedahl G.
    Neuropediatrics; 1993 Apr 01; 24(2):88-92. PubMed ID: 7687042
    [Abstract] [Full Text] [Related]

  • 8. Dysmorphic features: an important clue to the diagnosis and severity of fetal anticonvulsant syndromes.
    Kini U, Adab N, Vinten J, Fryer A, Clayton-Smith J, Liverpool and Manchester Neurodevelopmental Study Group.
    Arch Dis Child Fetal Neonatal Ed; 2006 Mar 01; 91(2):F90-5. PubMed ID: 16239295
    [Abstract] [Full Text] [Related]

  • 9. Valproate-induced neural tube defects in folate-binding protein-2 (Folbp2) knockout mice.
    Spiegelstein O, Merriweather MY, Wicker NJ, Finnell RH.
    Birth Defects Res A Clin Mol Teratol; 2003 Dec 01; 67(12):974-8. PubMed ID: 14745917
    [Abstract] [Full Text] [Related]

  • 10. Valproic acid increases formation of reactive oxygen species and induces apoptosis in postimplantation embryos: a role for oxidative stress in valproic acid-induced neural tube defects.
    Tung EW, Winn LM.
    Mol Pharmacol; 2011 Dec 01; 80(6):979-87. PubMed ID: 21868484
    [Abstract] [Full Text] [Related]

  • 11. VPA-induced neural tube defects in mice. I. Altered metabolism of sulfur amino acids and glutathione.
    Hishida R, Nau H.
    Teratog Carcinog Mutagen; 1998 Dec 01; 18(2):49-61. PubMed ID: 9704382
    [Abstract] [Full Text] [Related]

  • 12. Valproic acid embryopathy: report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature.
    Kozma C.
    Am J Med Genet; 2001 Jan 15; 98(2):168-75. PubMed ID: 11223853
    [Abstract] [Full Text] [Related]

  • 13. S-2-pentyl-4-pentynoic hydroxamic acid and its metabolite s-2-pentyl-4-pentynoic acid in the NMRI-exencephaly-mouse model: pharmacokinetic profiles, teratogenic effects, and histone deacetylase inhibition abilities of further valproic acid hydroxamates and amides.
    Eikel D, Hoffmann K, Zoll K, Lampen A, Nau H.
    Drug Metab Dispos; 2006 Apr 15; 34(4):612-20. PubMed ID: 16415118
    [Abstract] [Full Text] [Related]

  • 14. Anticonvulsant profile and teratogenic evaluation of potent new analogues of a valproic acid urea derivative in NMRI mice.
    Okada A, Noyori H, Yagen B, Shimshoni JA, Bialer M, Fujiwara M.
    Birth Defects Res B Dev Reprod Toxicol; 2009 Oct 15; 86(5):394-401. PubMed ID: 19830722
    [Abstract] [Full Text] [Related]

  • 15. Prediction of embryotoxic effects of valproic acid-derivatives with molecular in vitro methods.
    Lampen A, Göttlicher M, Nau H.
    ALTEX; 2001 Oct 15; 18(2):123-6. PubMed ID: 11378687
    [Abstract] [Full Text] [Related]

  • 16. Amidic modification of valproic acid reduces skeletal teratogenicity in mice.
    Okada A, Kurihara H, Aoki Y, Bialer M, Fujiwara M.
    Birth Defects Res B Dev Reprod Toxicol; 2004 Feb 15; 71(1):47-53. PubMed ID: 14991910
    [Abstract] [Full Text] [Related]

  • 17. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort.
    Omtzigt JG, Los FJ, Grobbee DE, Pijpers L, Jahoda MG, Brandenburg H, Stewart PA, Gaillard HL, Sachs ES, Wladimiroff JW.
    Neurology; 1992 Apr 15; 42(4 Suppl 5):119-25. PubMed ID: 1574165
    [Abstract] [Full Text] [Related]

  • 18. Teratogenicity of sodium valproate.
    Alsdorf R, Wyszynski DF.
    Expert Opin Drug Saf; 2005 Mar 15; 4(2):345-53. PubMed ID: 15794725
    [Abstract] [Full Text] [Related]

  • 19. Valproate teratogenicity and epilepsy syndrome.
    Bromfield EB, Dworetzky BA, Wyszynski DF, Smith CR, Baldwin EJ, Holmes LB.
    Epilepsia; 2008 Dec 15; 49(12):2122-4. PubMed ID: 18557775
    [Abstract] [Full Text] [Related]

  • 20. Teratogenic effects of sodium valproate in mice and rats at midgestation and at term.
    Menegola E, Broccia ML, Nau H, Prati M, Ricolfi R, Giavini E.
    Teratog Carcinog Mutagen; 1996 Dec 15; 16(2):97-108. PubMed ID: 8875740
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 133.